Document:

Amendment to the Stock and Note Purchase Agreement

 Exhibit 10.1 
 

 
 October 18, 2006 
 LFB Biotechnologies 
 3, avenue des Tropiques 
 Les Ulis

 91958 Courtaboeuf 
 France 
 Re: Amendment to the Stock and Note Purchase Agreement 
 This letter
sets forth an amendment to the Stock and Note Purchase Agreement dated as of September 29, 2006 (the “Agreement”) between LFB Biotechnologies (the “Purchaser”) and GTC Biotherapeutics, Inc. (the “Company”) and
shall be interpreted in accordance with the terms thereof. Capitalized terms not defined herein shall have the meanings set forth in the Agreement. 
 The
second paragraph of Section 3 of the Agreement is hereby amended and restated in its entirety as follows: 
 “Upon approval by the SEC of such
preliminary proxy or consent solicitation statement or, if the SEC has not reviewed such statement, promptly after the expiration of 10 calendar days from the filing of the preliminary proxy statement or consent solicitation statement, the Company
shall file a definitive proxy statement or consent solicitation statement and call and hold a shareholder meeting within 40 calendar days of the filing of such definitive proxy statement to obtain the Shareholder Approvals.” 
  

			
	GTC BIOTHERAPEUTICS, INC.
		
	By:	 	 /s/ John B. Green

		 	John B. Green
		 	Senior Vice President and Chief Financial Officer

  

			
	AGREED:
	
	LFB BIOTECHNOLOGIES S.A.S.U.
		
	By:	 	 /s/ Christian Béchon

		 	Christian Béchon
		 	PresidentAmendment No. 2 to the Stock and Note Purchase Agreement

 Exhibit 10.2 
 

 
 March 25, 2008 
 LFB
Biotechnologies, S.A.S.U. 
 3, avenue des Tropiques 
 Les Ulis

 91958 Courtaboeuf 
 France 
  

	Re:	Amendment No. 2 to the Stock and Note Purchase Agreement 

 This
letter sets forth a second amendment to the Stock and Note Purchase Agreement dated as of September 29, 2006 between LFB Biotechnologies (the “Purchaser”) and GTC Biotherapeutics, Inc. (the “Company”), as
amended by the amendment dated October 18, 2006 (as previously amended, the “Agreement”). This amendment shall be interpreted in accordance with the terms of the Agreement. Capitalized terms not defined herein shall have the
meanings set forth in the Agreement. 
  

	1.	Non-Exercise by the Company of Mandatory Conversion Right 

 Subject
to the simultaneous conversion of shares of Series D Preferred Stock pursuant to Section 4 below, and as an inducement for the Purchaser to make such conversion, the Company irrevocably agrees not to exercise its right provided under
Section 4.4.6 (as corrected in accordance with Section 3 below) of the Company’s Articles of Amendment designating the Series D Preferred Stock, as filed on October 2, 2007 with the Secretary of the Commonwealth of the
Commonwealth of Massachusetts (the “Articles of Amendment”), to require conversion of all of the outstanding shares of Series D Preferred Stock into shares of Common Stock if the right of the Purchaser to nominate the
“Purchaser Designee” pursuant to the Agreement automatically terminates pursuant to clause (iii) of Section 9(c) of the Agreement after conversion of more than 50% of the shares of Series D Preferred Stock issued to the
Purchaser. 
  

	2.	Amendment to Section 9 of the Agreement  

 Section 9(c) of
the Agreement is hereby amended and restated in its entirety as follows: 
 “(c) Ownership Requirements. After June 30, 2012,
or if the annual shareholder meeting for 2012 in which directors are elected is held after June 30, 2012, after the date of such meeting, the Purchaser’s right to nominate the Purchaser Designee, including any successor, shall
automatically terminate upon the occurrence of either (i) the Purchaser’s ownership of Common Stock of the Company declining to less than ten percent (10%) on an as-converted basis and termination of the Development Agreement or
(ii) the Purchaser’s ownership of Common Stock of the Company declining to less than five percent (5%) on an as-converted basis. For purposes of this Agreement, “ownership” shall be determined in accordance with the rules
for “beneficial ownership” set forth in the Rights Agreement referenced in Section 10(e) below, and ownership on an “as-converted basis” shall mean inclusion of all shares of Common Stock issuable upon conversion or exercise
of convertible or exercisable securities of the Company in the number of outstanding shares of Common Stock.” 

 LFB Biotechnologies 
 March
25, 2008 
  Page
 2
 of 3 
  

	3.	Correction to Charter Amendment 

 The Company and the Purchaser
agree that the Company shall file Articles of Correction to its Restated Articles of Organization to correct a typographical error in Section 4.4.6 of the Articles of Amendment to correctly refer to Section 9(c) of the Stock Purchase
Agreement dated as of September 29, 2006 instead of Section 9(b). 
  

	4.	Exercise by the Purchaser of Optional Conversion Right 

 Pursuant to
Section 4.4.5 of the Articles of Amendment, immediately following, and in consideration of, the effectiveness of the amendment to Section 9(c) of the Agreement as set forth in Section 1 above, the Purchaser irrevocably elects, and
irrevocably instructs the Company, to convert 14,500 shares (the “Converted Series D Shares”) of the shares of Series D Preferred Stock that the Purchaser holds into 14,500,000 shares (the “Conversion Shares”) of
Common Stock registered in the name of the Purchaser. Notwithstanding anything to the contrary in Section 4.4.5(c) of the Articles of Amendment, the date of this amendment shall be the conversion date of the conversion of the Converted Series D
Shares and the issuance of the Conversion Shares shall be effective as of the close of business on the date hereof; and the Converted Series D Shares shall no longer be deemed to be outstanding, and all rights with respect to such shares shall
terminate, at the close of business on the date hereof, except only for the right of the Purchaser to receive the Common Shares in exchange therefor. The Purchaser shall promptly surrender the certificates representing the Converted Series D Shares
and the Company shall promptly issue and deliver to the Purchaser a certificate representing the Conversion Shares and a replacement certificate for the remaining shares of Series D Preferred Stock held by the Purchaser. 
  

	4.	Miscellaneous 

 A. Effect on Agreement.
Except as specifically amended herein, the Agreement, and all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect. 
 B. Incorporation of Other Terms. Except as specifically amended herein, this amendment shall be governed by all the terms and provisions of the
Agreement. 
 C. This amendment may be executed in any number of counterparts, each of which shall be enforceable against the parties
actually executing such counterparts, and all of which together shall constitute one instrument. 
  

			
	GTC BIOTHERAPEUTICS, INC.
		
	By:	 	 /s/ John B. Green

		 	John B. Green
		 	Senior Vice President and Chief Financial Officer

 LFB Biotechnologies 
 March
25, 2008 
  Page
 3
 of 3 
  

			
	AGREED:
	
	LFB BIOTECHNOLOGIES, S.A.S.U.
		
	By:	 	 /s/ Christian Béchon

		 	Christian Béchon
		 	PresidentAlberto-Culver Company Employee Stock Option Plan of 2006, as amended on 1/24/08

 Exhibit 10(a) 
 ALBERTO-CULVER COMPANY 
 EMPLOYEE STOCK OPTION PLAN OF 2006 
 (as amended through January 24, 2008) 
  

	1.	Purpose of ACSOP 

 The Alberto-Culver Company
Employee Stock Option Plan of 2006 (hereinafter called the “ACSOP”) is intended to encourage ownership of the Common Stock of Alberto-Culver Company (the “Company”) by eligible key employees of the Company and its subsidiaries
and to provide incentives for them to make maximum efforts for the success of the business. Options granted under the ACSOP will be non-qualified options (not incentive options as defined in Section 422 of the Internal Revenue Code of 1986 and
the rules and regulations promulgated thereunder (the “Code”)). 
  

	2.	Eligibility 

 Key employees of the Company and its
subsidiaries who perform services which contribute materially to the management, operation and development of the business (“Optionees”) will be eligible to receive options under the ACSOP. 
  

	3.	Administration 

 The Compensation and Leadership
Development Committee of the Board of Directors of the Company (the “Committee”) shall have full power and authority, subject to the express provisions of the ACSOP, to determine the purchase price of the stock covered by each option, the
Optionees to whom and the time or times at which options shall be granted, the terms and conditions of the options, including the terms of payment thereof, and the number of shares of stock to be covered by each option. The Committee shall have full
power to construe, administer and interpret the ACSOP, and full power to adopt such rules and regulations as the Committee may deem desirable to administer the ACSOP. No member of the Committee shall be liable for any action or determination made in
good faith with respect to the ACSOP or any option thereunder. Determinations by the Committee under the ACSOP need not be uniform and may be made by it selectively among Optionees, whether or not such persons are similarly situated. The
determination of the Committee as to any disputed question arising under the ACSOP, including questions of construction and interpretation, shall be final, conclusive and binding. 
 The Committee may, in its discretion, delegate to a committee of member(s) of the Committee its authority with respect to such matters under the ACSOP
and options granted under the ACSOP as the Committee may specify. 
 The Committee shall be comprised solely of members each of whom shall be
an “outside director” within the meaning of Section 162(m) of the Code, and a “non-employee director” within 

  

 1 

 
the meaning of Section 16 (“Section 16”) of the Securities Exchange Act of 1934 and the rules and regulations thereunder (“Exchange
Act”), provided, however, that if any member of the Committee is not (i) an “outside director” within the meaning of Section 162(m) of the Code or (ii) a “non-employee director” within the meaning of
Section 16, the Committee shall set up a subcommittee comprised solely of outside directors and non-employee directors for purposes of all matters arising under this ACSOP involving “officers” within the meaning of Rule 16a-1(f) under
Section 16, and “covered employees” within the meaning of Section 162(m) of the Code for the plan year at issue. 
  

	4.	Number of Shares of Stock to be Offered 

 The
Committee may authorize from time to time the issuance pursuant to the ACSOP of shares not to exceed 9,000,000 of the Company’s Common Stock in the aggregate plus the number of shares of the Company’s Common Stock subject to Substitute
Options as provided in Section 14, subject to adjustment under paragraph 10 hereof. Such shares of Common Stock which may be issued pursuant to options granted under the ACSOP may be authorized and unissued shares or issued and reacquired
shares as the Committee from time to time may determine. If any option granted under the ACSOP shall terminate or be surrendered or expire unexercised in whole or in part, the shares of stock so released from such option may be made the subject of
additional options granted under the ACSOP. Notwithstanding anything to the contrary contained herein, shares of Common Stock (i) tendered in payment of the purchase price, (ii) tendered or withheld by the Company in payment of any tax
withholding obligation, and (iii) repurchased by the Company with option proceeds, shall not in each case be made the subject of additional option grants under the ACSOP. 
  

	5.	Option Price 

 The purchase price under each option
granted pursuant to the ACSOP shall be determined by the Committee but shall not be less than the Fair Market Value (as defined below) of the Company’s Common Stock on the date the option is granted. For purposes of the ACSOP, “Fair Market
Value” shall mean the average of the high and low transaction prices of a share of Common Stock of the Company as reported in the New York Stock Exchange Composite Transactions on the date as of which such value is being determined or, if there
shall be no reported transactions for such date, on the next preceding date for which transactions were reported. 
  

	6.	Grant of Options 

 The Committee may not grant to
any individual Optionee in any fiscal year an option or options with respect to more than 600,000 shares of Common Stock. 
  

	7.	Term and Exercise of Options 

 (a) Each option
granted shall provide that it is not exercisable after the expiration of ten (10) years from the date the option is granted, or such shorter period as the Committee determines (the “Expiration Date”), and each option shall be subject
to the following limitations with respect to its exercise: 
  

	 	(i)	Except as otherwise provided in paragraphs 7(b), 8(a) or 11(a) hereof, no option may be exercised until the day preceding the anniversary date of the grant of the option.

  

 2 

	 	(ii)	Except as otherwise provided in paragraphs 7(b), 8(a) or 11(a) hereof, on the day preceding the anniversary date of the grant of the option in each of the four calendar years
immediately following the year of the grant of the option, the right to purchase twenty-five percent (25%) of the total number of shares of stock specified in the option shall accrue to the Optionee. Subject to paragraph 8 hereof, each such
right to purchase may be exercised, in whole or in part, at any time after such right accrues and prior to the Expiration Date of the option. 

 (b) Notwithstanding the foregoing or paragraph 8 hereof, the Committee may in its discretion (i) specifically provide at the date of grant for another time or times of exerciseability; (ii) at any time prior
to the Expiration Date or termination of any option previously granted, accelerate the exercisability of any option subject to such terms and conditions as the Committee deems necessary or appropriate to effectuate the purpose of the ACSOP; or
(iii) at any time prior to the Expiration Date or termination of any option previously granted, extend the term of any option (including such options held by officers or directors) for such additional period as the Committee, in its discretion,
shall determine; provided that the term of an option shall not be extended beyond the Expiration Date of that option. In no event, however, shall the aggregate option period with respect to any option, including the original term of the option and
any extensions thereof, exceed ten years. 
 (c) An option may be exercised (subject to the receipt of payment) by giving written notice to
the Company specifying the number of shares to be purchased. The full purchase price for such shares may be paid (i) in cash, (ii) by check, (iii) by delivery of previously owned shares of Common Stock, or (iv) by a combination
of these methods of payment. However, under no circumstances may any Optionee deliver previously owned shares of Common Stock obtained from the exercise of stock options under any option plan of the Company or the vesting of shares restricted under
any restricted stock plan of the Company or the Management Bonus Plan during the six months immediately preceding the exercise date. Payment must be received by the Company before any exercise is consummated. For purposes of the delivery of
previously owned shares of Common Stock, the per share value of such shares shall be the Fair Market Value on the date of exercise. 
 (d) At
any time when an Optionee is required to pay to the Company an amount required to be withheld under applicable tax laws in connection with the exercise of an option (calculated by taking the minimum statutory withholding rates for federal, foreign,
state and local tax purposes including payroll taxes, applicable to the income generated by the Optionee by such exercise), the Optionee may satisfy this obligation (i) in cash, (ii) by check, (iii) by delivery of previously owned
shares of Common Stock, (iv) by making an election to have the Company withhold shares of Common Stock, or (v) by a combination of these methods of payment, in each case having a value equal to the amount required to be withheld. The
Optionee must specify the method of satisfying this obligation on or before the date of exercise. The value of the shares to be withheld or delivered shall be based on the Fair Market Value of the Common Stock on the date of exercise. 
  

 3 

	8.	Continuity of Employment 

 (a) Each option shall be
subject to the following in addition to the restrictions set forth in paragraphs 6 and 7 hereof: 
  

	 	(i)	Upon the death of an Optionee, all unvested options shall immediately vest and the executors or administrators of his or her estate or legatees or distributees shall have the right
during the one (1) year period following his or her death (but not after the Expiration Date of such option) to exercise any unexercised options. 

  

	 	(ii)	Upon an Optionee’s termination of employment due to disability, all unvested options shall immediately vest and the Optionee’s option shall terminate one (1) year
after his or her termination of employment (but not after the Expiration Date of such option). For purposes of the ACSOP, “disability” shall have the meaning provided in the Company’s applicable long-term disability plan and such
disability continues for more than three months or, in the absence of such a definition, when an Optionee becomes totally disabled as determined by a physician mutually acceptable to the Optionee and the Committee before attaining the age of
retirement as defined below and if such total disability continues for more than three months. Disability does not include any condition which is intentionally self-inflicted or caused by illegal acts of the Optionee. 

  

	 	(iii)	If an Optionee’s termination of employment is due to retirement, all options (or portions thereof) which are (a) vested at the time of retirement may be exercised for a
period of two (2) years following retirement (but not after the Expiration Date of such option) and (b) unvested at the time of retirement may be exercised for a period of five (5) years from the date of grant (but not after the
Expiration date of such option). Following retirement, options (or portions thereof) which are unvested at the time of retirement will continue to vest under such options’ vesting schedule for a period of five (5) years following
retirement. For purposes of the ACSOP, “retirement” shall be reached when an Optionee’s employment terminates and at the time of such termination the sum of such Optionee’s age and years of service as an employee of the Company
or any of its subsidiaries equals or exceeds 75 years (“Rule of 75”). 

  

	 	(iv)	If an Optionee’s termination of employment is for any reason other than death, retirement or physical disability, the Optionee’s option shall terminate three
(3) months after his or her termination of employment (but not after the Expiration Date of such option). 

 (b) Nothing
contained in the ACSOP or any option granted pursuant to the ACSOP shall confer upon any Optionee any right to be continued in the employment of the Company or any subsidiary or shall prevent the Company or any subsidiary from terminating an
Optionee’s employment at any time, with or without cause. The determination by the Committee of whether an authorized leave of absence constitutes a termination of employment shall be final, conclusive and binding. 
  

 4 

	9.	Non-Transferability of Options 

 An option granted
under the ACSOP shall not be assignable or transferable by an Optionee otherwise than by will or the laws of descent and distribution, and an option shall be exercisable during the lifetime of the Optionee only by him or her. Subject to the
following sentence, an option transferred by will or the laws of descent and distribution may only be exercised by the executors or administrators of his or her estate or any legatee or distributee during the one year period following the
Optionee’s death. In the event that at the time of the Optionee’s death the Optionee met the Rule of 75, an option transferred by will or the laws of descent and distribution may only be exercised by the legatee or distributee during the
period of time that the Optionee could have exercised such options at the time of his or her death and such options shall continue to vest as if the Optionee had not died. 
  

	10.	Adjustment upon Change in Stock 

 Each option, the
number and kind of shares subject to future options and the number of shares subject to options that may be granted to an Optionee in any fiscal year under the ACSOP shall be adjusted, as may be determined to be equitable in the sole and absolute
discretion of the Committee, in the event there is any change in the outstanding Common Stock, or any event that could cause a change in the outstanding Common Stock, including, without limitation, by reason of a stock dividend, recapitalization,
reclassification, issuance of Common Stock, issuance of rights to purchase Common Stock, extraordinary cash dividend, issuance of securities convertible into or exchangeable for Common Stock, merger, consolidation, stock split, reverse stock split,
spin-off, combination, exchange or conversion of shares, or any other similar type of event. The Committee’s determination of any adjustment pursuant to this paragraph 10 shall be final, conclusive and binding. 
  

	11.	Change in Control 

 (a) (1) Notwithstanding any
provision of the ACSOP, in the event of a Change in Control, all outstanding options shall immediately be exercisable in full and shall be subject to the provisions of paragraph 11(a)(2) or 11(a)(3), to the extent that either such paragraph is
applicable. If neither paragraph 11(a)(2) or 11(a)(3) is applicable, in whole or in part, the Committee shall make such reasonable adjustments to the exercise price, number of shares subject to options, type of shares subject to options, and/or any
other term so that no outstanding option is adversely affected or impaired by such Change in Control. 
 (2) Notwithstanding
any provision of the ACSOP, in the event of a Change in Control in connection with which the holders of shares of the Company’s Common Stock receive shares of common stock that are registered under Section 12 of the Exchange Act, all
outstanding options shall immediately be exercisable in full and there shall be substituted for each share of the Company’s Common Stock available under the ACSOP, whether or not then subject to an outstanding option, the number and class of
shares into which each outstanding share of the Company’s Common Stock shall be converted pursuant to such Change in Control. In the event of any such substitution, the purchase price per share of each option and/or the number of shares subject
to options shall be appropriately adjusted by the Committee, such adjustments to be made without an increase in the aggregate purchase price. 
  

 5 

 (3) Notwithstanding any provision in the ACSOP, in the event of a Change in Control in
connection with which the holders of the Company’s Common Stock receive consideration other than shares of common stock that are registered under Section 12 of the Exchange Act, each outstanding option shall be surrendered to the Company
by the holder thereof, and each such option shall immediately be cancelled by the Company, and the holder shall receive, within ten (10) days of the occurrence of such Change in Control, a cash payment from the Company in an amount equal to the
number of shares of the Company’s Common Stock then subject to such option, multiplied by the excess, if any, of (i) the greater of (A) the highest per share price offered to holders of common stock of the Company in any transaction
whereby the Change in Control takes place or (B) the Fair Market Value of a share of the Company’s Common Stock on the date of occurrence of the Change in Control over (ii) the purchase price per share of the Company’s Common
Stock subject to the option. The Company may, but is not required to, cooperate with any person who is subject to Section 16 of the Exchange Act to assure that any cash payment in accordance with the foregoing to such person is made in
compliance with Section 16 of the Exchange Act and the rules and regulations thereunder providing for an exemption from Section 16(b) of the Exchange Act. 
 (b) “Change in Control” means: 
 (1) The occurrence of any one or more of the
following events: 
 (A) The acquisition by any individual, entity or group (a “Person”), including any
“person” within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act of beneficial ownership within the meaning of Rule 13d-3 promulgated under the Exchange Act of both (x) 20% or more of the combined voting power of
the then outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”) and (y) combined voting power of Outstanding Company Voting Securities in excess of
the combined voting power of the Outstanding Company Voting Securities held by the Exempt Persons (as such term is defined in paragraph 11(c)); provided, however, that a Change in Control shall not result from an acquisition of Company
Voting Securities: 
 (i) directly from the Company, except as otherwise provided in paragraph 11(b)(2)(A); 
 (ii) by the Company, except as otherwise provided in paragraph 11(b)(2)(B); 
 (iii) by an Exempt Person; 
 (iv) by an employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company; or 
  

 6 

 (v) by any corporation pursuant to a reorganization, merger or consolidation involving
the Company, if, immediately after such reorganization, merger or consolidation, each of the conditions described in clauses (i) and (ii) of paragraph 11(b)(1)(C) shall be satisfied. 
 (B) The cessation for any reason of the members of the Incumbent Board (as such term is defined in paragraph 11(d)) to constitute at least
a majority of the Board of Directors of the Company (hereinafter called the “Board”). 
 (C) Consummation of a
reorganization, merger or consolidation unless, in any such case, immediately after such reorganization, merger or consolidation: 
 (i) more than 60% of the combined voting power of the then outstanding securities of the corporation resulting from such reorganization, merger or consolidation entitled to vote generally in the election of directors is then beneficially
owned, directly or indirectly, by all or substantially all of the individuals or entities who were the beneficial owners of the combined voting power of all of the Outstanding Company Voting Securities immediately prior to such reorganization,
merger or consolidation; and 
 (ii) at least a majority of the members of the board of directors of the corporation
resulting from such reorganization, merger or consolidation were members of the Incumbent Board at the time of the execution of the initial agreement or action of the Board providing for such reorganization, merger or consolidation. 
 (D) Consummation of the sale or other disposition of all or substantially all of the assets of the Company other than (x) pursuant to
a tax-free spin-off of a subsidiary or other business unit of the Company or (y) to a corporation with respect to which, immediately after such sale or other disposition: 
 (i) more than 60% of the combined voting power of the then outstanding securities thereof entitled to vote generally in the election of
directors is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners of the combined voting power of all of the Outstanding Company Voting Securities immediately
prior to such sale or other disposition; and 
  

 7 

 (ii) at least a majority of the members of the board of directors thereof were members
of the Incumbent Board at the time of the execution of the initial agreement or action of the Board providing for such sale or other disposition. 
 (E) Approval by the stockholders of the Company of a plan of complete liquidation or dissolution of the Company. 
 (2) Notwithstanding the provisions of paragraph 11(b)(1): 
 (A) no acquisition of Company
Voting Securities shall be subject to the exception from the definition of Change in Control contained in clause (i) of paragraph 11(b)(1)(A) if such acquisition results from the exercise of an exercise, conversion or exchange privilege unless
the security being so exercised, converted or exchanged was acquired directly from the Company; and 
 (B) for purposes of
clause (ii) of paragraph 11(b)(1)(A), if any Person (other than the Company, an Exempt Person or any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company) shall, by reason
of an acquisition of Company Voting Securities by the Company, become the beneficial owner of (x) 20% or more of the combined voting power of the Outstanding Company Voting Securities and (y) combined voting power of Outstanding Company
Voting Securities in excess of the combined voting power of the Outstanding Company Voting Securities held by the Exempt Persons, and such Person shall, after such acquisition of Company Voting Securities by the Company, become the beneficial owner
of any additional Outstanding Company Voting Securities and such beneficial ownership is publicly announced, such additional beneficial ownership shall constitute a Change in Control. 
 (c) “Exempt Person” (and collectively, the “Exempt Persons”) means: 
 (1) Leonard H. Lavin or Bernice E. Lavin; 
 (2) any descendant of Leonard H. Lavin and Bernice E. Lavin or the spouse of any such descendant; 
 (3) the estate of any of the persons described in paragraph 11(c)(1) or (2); 
 (4) any trust or similar arrangement
for the benefit of any person described in paragraph 11(c)(1) or (2); or 
  

 8 

 (5) the Lavin Family Foundation or any other charitable organization established by any
person described in paragraph 11(c)(1) or (2). 
 (d) “Incumbent Board” means those individuals who, as of January 1, 2007,
constitute the Board, provided that: 
 (1) any individual who becomes a director of the Company subsequent to such
date whose election, or nomination for election by the Company’s stockholders, was approved either by the vote of at least a majority of the directors then comprising the Incumbent Board or by the vote of at least a majority of the combined
voting power of the Outstanding Company Voting Securities held by the Exempt Persons shall be deemed to have been a member of the Incumbent Board; and 
 (2) no individual who was initially elected as a director of the Company as a result of an actual or threatened solicitation by a Person other than the Board or the Exempt Persons for the purpose of opposing a
solicitation by any other Person with respect to the election or removal of directors, or any other actual or threatened solicitation of proxies or consents by or on behalf of any Person other than the Board or the Exempt Persons shall be deemed to
have been a member of the Incumbent Board. 
  

	12.	Amendment and Discontinuance 

 The Committee or the
Board, without further approval of the stockholders, may, at any time and from time to time, suspend or discontinue the ACSOP in whole or in part or amend the ACSOP in such respects as the Committee or the Board may deem proper and in the best
interests of the Company or as may be advisable, provided, however, that no suspension or amendment shall be made which would: 
  

	 	(i)	Adversely affect or impair any option previously granted under the ACSOP without the consent of the Optionee, or 

  

	 	(ii)	Except as specified in paragraph 10, increase the total number of shares for which options may be granted under the ACSOP or decrease the minimum price at which options may be
granted under the ACSOP. 

  

	13.	Stockholder Adoption 

 The ACSOP was approved by the
stockholders of the Company on November 13, 2006 and became effective on November 16, 2006, the date that the Delaware corporation having the name or previously having the name New Sally Holdings, Inc. (“New Sally”) distributed
the then outstanding Common Stock of the Company to holders of common stock, $.01 par value per share, of New Sally (the “Distributions”). 
  

	14.	Substitute Awards 

 Upon the Distributions, the
Committee shall be authorized to grant substitute options under the ACSOP (“Substitute Options”) to purchase Common Stock of the Company, in accordance with 

  

 9 

 
the terms of the Employee Matters Agreement, dated as of June 19, 2006, among New Sally, Sally Holdings, Inc., Alberto-Culver Company, as then
constituted, and the Company (the “Employee Matters Agreement”), to holders of options to purchase common stock of New Sally (“New Sally Options”). The aggregate number of shares of Common Stock subject to Substitute Options
shall not exceed the number determined by multiplying (i) the number of shares of New Sally common stock subject to the New Sally Options that are converted into New Alberto Options pursuant to the Employee Matters Agreement by (ii) the
ratio of the Alberto-Culver Pre-Distribution Stock Price over the New Alberto-Culver Post Distribution Stock Price, as such terms are defined in the Employee Matters Agreement. The Committee shall determine the exercise price and number of shares of
Common Stock subject to each Substitute Option in a manner that preserves the intrinsic value of the New Sally Option to which such Substitute Option relates. Except for the terms and conditions set forth in paragraph 7(b) of the ACSOP, the terms
and conditions of each Substitute Option, including, without limitation, the Expiration Date of the option, the duration of the exercise period and the method of exercise shall be the same as those of the New Sally Option to which the Substitute
Option relates. 
  

 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]